


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-5.57%
+0.62%
+3.33%
+3.39%
CYTK
Cytokinetics Incorpo
$76.94

Login to see Cytokinetics Incorpo (CYTK) Stock IQ rating
Get instant clarity on whether to Buy, Hold, or Avoid.
Strengths

Expands stock buyback program
Risk Analysis

Trading above its fair value
CYTK Price Performance
$60.69 (+26.78%)
$62.22 (+23.66%)
$61.37 (+25.37%)
$33.11 (+132.38%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Trading above its fair value
CYTK Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CYTK Street Sentiment is bullish and have positive views on the near-term outlook
CYTK has Low risk level

Sentiments overview associated with events and the stock performance
Recent Upgrades and Downgrades
Dec 24, 2025
Reiterate
Overweight
Morgan Stanley
Dec 23, 2025
Reiterate
Outperform
Citizens
Dec 23, 2025
Reiterate
Outperform
RBC
Dec 23, 2025
Reiterate
Overweight
Barclays
Dec 22, 2025
Reiterate
Buy
HC Wainwright & Co.
SNY
Sanofi
44.29
-1.40%
AZN
Astrazeneca
187.03
-1.44%
NVO
Novo Nordisk A/S
44.96
+1.33%
What is CYTK current stock price?
What is CYTK current Stock IQ?
What is CYTK RSI signal right now?
What is CYTK analyst price target and upside potential?
What do analysts say about CYTK stock?
What is CYTK momentum trend right now?
What are CYTK stock strengths?
What is CYTK Risk Level?
Should I buy CYTK stock right now?
Is CYTK a Strong Buy right now?
What is CYTK market cap and volume?
What factors influence CYTK's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
CYTK
Cytokinetics Incorpo
Current Price
$76.94
SNY
Sanofi
44.29
-1.40%
AZN
Astrazeneca
187.03
-1.44%
NVO
Novo Nordisk A/S
44.96
+1.33%

CYTK Price Performance
$60.69 (+26.78%)
$62.22 (+23.66%)
$61.37 (+25.37%)
$33.11 (+132.38%)
CYTK Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Trading above its fair value
CYTK Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CYTK Street Sentiment is bullish and have positive views on the near-term outlook
CYTK has Low risk level

Overall Wall Street Rating
CYTK Stock IQ
Stock Insights
Strengths

Expands stock buyback program
Risk Analysis

Trading above its fair value
CYTK Trading Signals
CYTK at $78.06 is within 2.67% of its 52-week high of $80.20. This proximity suggests potential breakout zone ahead.
CYTK Stock IQ dropped from 4.96 to 3.63, reflecting a weakened outlook.
CYTK Stock IQ sentiment changed from Strong Bullish to Bullish, reflecting a changed outlook.
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CYTK Stock trends
CYTK Stock performance
CYTK Stock analysis
CYTK investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.